NEW YORK, April 30, 2010 (GLOBE NEWSWIRE) -- Geller Biopharm, Inc. announced today that they have successfully advised BELLUS Health of LAVAL, Quebec, Canada in its transaction with Celtic Therapeutics with respect to Phase III investigational product candidate KIACTA™ (eprodisate) for the treatment of AA Amyloidosis. A news release presenting the details of the transaction was issued jointly by BELLUS Health and Celtic Therapeutics on April 29, 2010.
